MedPath

Innate Immunity in Allergic Asthma

Recruiting
Conditions
Asthma
Registration Number
NCT06068335
Lead Sponsor
University of Central Florida
Brief Summary

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Participants must be at least 18 years of age
  • no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma.
Exclusion Criteria
  • Pregnant women and prisoners will be excluded from the study.
  • Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine which parameters of the established type-2 signature obtained in vitro is significantly different between healthy controls, allergic individuals, and asthmatic individuals ex vivo.1 year
Secondary Outcome Measures
NameTimeMethod
To determine ex vivo whether any of the identified disease-specific type-2 parameters can be modified (brought back to healthy control levels) through the use of investigational compounds.1 year

Trial Locations

Locations (1)

University of Central Florida

🇺🇸

Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath